查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球重組 DNA 技術市場-2022-2029
市場調查報告書
商品編碼
1140722

全球重組 DNA 技術市場-2022-2029

Global Recombinant DNA Technology Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

2021 年重組 DNA 技術市場價值 1567.5 億美元。預計在預測期內（2022-2029 年）的複合年增長率為 4.80%。

重組 DNA 技術涉及將攜帶感興趣基因的 DNA 插入基因組。它通過拼接來自兩個不同物種的 DNA 分子並將它們插入宿主生物體來創建新的遺傳組合。新的基因組合包含來自基因組中未發現的多種來源的遺傳物質。結果，生產了轉基因生物和產品。轉基因生物（例如微生物、動物和植物）已被證明可以提高產品產量並增強適應性，從而更好地生存。

幾家公司正在使用重組 DNA 技術生產胰島素、follistim、人類生長激素、單克隆抗體、人類白蛋白、疫苗、基因治療和其他治療劑。它還用於生產轉基因作物、克隆動物、生物農藥、生物燃料和其他產品。

市場動態

重組 DNA 技術的進步推動市場增長

市場正在見證開發高效診斷工具和療法的技術進步。 Bac-to-Bac 桿狀病毒表達系統的引入提供了一種在昆蟲細胞中有效生產攜帶感興趣基因的重組桿狀病毒的方法。與耗時的限制性□克隆相比，Bac-to-Bac 桿狀病毒表達系統加速了克隆反應。 CRISPR技術是一種可以修改DNA序列並改變基因功能的技術。它用於各種目的，例如糾正遺傳缺陷、治療和預防疾病傳播以及改良農作物。正在引入生殖細胞基因療法，其中將 DNA 移植到產生卵子和精子的細胞中，這些細胞是體內的生殖細胞。這種治療可有效糾正導致代代相傳疾病的基因突變。體細胞基因療法是一種將 DNA 引入體內組織的治療方法。這種治療針對的是不會代代相傳的身體細胞。

預計基因工程產品開發的資金和投資將在預測期內推動市場增長。

一些組織、協會和實驗室正在增加對重組產品開發的資金和投資。例如，2020 年 3 月，流行病防範創新聯盟 (CEPI) 與 Novavax 和牛津大學簽署了一項合作協議，投資 440 萬美元，以快速開發針對 COVID-19 的重組疫苗產品。根據協議條款，CEPI 將向 Novavax 提供初始資金，為 I 期臨床試驗做準備。牛津大學將幫助製造臨床前和 I 期試驗所需的疫苗原材料。 2020 年 7 月，美國衛生與公眾服務部 (HHS) 和國防部 (DoD) 授予賽諾菲和葛蘭素史克 21 億美元，用於開發和製造基於重組蛋白的 COVID-19 疫苗。衛生與公眾服務部 (HHS) 和國防部 (DoD) 將為“曲速行動”提供資金。

與使用轉基因產品相關的道德問題阻礙了市場增長

使用轉基因產品存在一些道德問題。例如，基因工程產品是否與天然產品具有生物等效性，基因工程蛋白質會引起免疫原性反應，從而限制它們的使用。重組產品的使用正在篡改基因組。動物和人類系統之間免疫易感性的差異已證明是災難性的結果。抗體 TGN1412 在類風濕性關節炎和 B 細胞慢性淋巴細胞白血病患者中的 Tegenero 試驗揭示了其毒性。種系基因療法最終將通過去除所謂的壞基因來減少人類基因庫。由於基因治療費用高昂，只有富人才能受益。基因療法的普及可能會降低社會對與眾不同的人的接受程度。對於基因治療以增強身高、智力和運動能力等基本人類特徵也存在倫理問題。

COVID-19 影響分析

由於 COVID-19 大流行，全球重組 DNA 技術市場經歷了巨大的增長。幾家生物製藥公司專注於使用重組 DNA 技術開發疫苗以預防 COVID-19。隨著感染 COVID-19 的人數增加，用於開發 COVID-19 重組疫苗的研發活動正在加強。該管道由多種病毒載體、核酸疫苗和正在為 COVID-19開發的抗原呈遞細胞組成。病毒載體疫苗是使用重組 DNA 技術克隆具有降低的致病性的重組病毒和編碼病毒抗原的基因。蛋白質疫苗由從病毒或病毒感染細胞中純化的蛋白質、重組蛋白質和病毒樣顆粒組成。

多個機構、組織、研究機構和公司正在參與聯合研究，以開發針對 COVID-19 傳染病的重組疫苗。例如，2020 年 4 月，賽諾菲與葛蘭素史克簽訂了一項合作研究協議，以開發 COVID-19 的輔助疫苗。根據協議，賽諾菲將提供基於重組 DNA 技術的 S 蛋白 COVID-19 抗原。葛蘭素史克將提供其經過驗證的大流行佐劑技術。這可以減少單次注射所需的疫苗蛋白量，從而可以生產更多疫苗並保護更多人。

流行病學

慢性病是全球死亡率和發病率的主要原因。根據美國疾病控制和預防中心 (CDC) 的數據，每 10 名成年人中就有 6 人患有慢性病。據說十分之四的人患有兩種或兩種以上的慢性疾病。心髒病、癌症、慢性肺病、中風、阿爾茨海默病、糖尿病和慢性腎病是最常見的慢性疾病。吸煙、營養不良、缺乏運動、過度飲酒和其他疾病會增加患慢性病的風險。根據美國糖尿病協會的數據，美國約有 3420 萬人患有糖尿病。其中，約 160 萬人患有 1 型糖尿病。

市場細分

重組DNA技術市場有望以醫療領域為主

按產品類型，由於重組 DNA 技術在藥品生產中的廣泛應用，預計醫療領域將佔重組 DNA 技術治療市場的最大份額。重組 DNA 技術是生產新藥、更安全或更有效的常規藥物以及與常規藥物相同的物質的技術。在醫學領域，它們分為治療藥物、人體蛋白質和疫苗。重組 DNA 技術用於生產人類蛋白質，用作診斷工具和治療劑，並可治療多種遺傳相關疾病。多種重組蛋白，如重組激素、干擾素、白細胞介素、生長因子、腫瘤壞死因子、凝血因子、溶栓劑和□，可用於治療糖尿病等疾病。侏儒症、心肌梗塞、充血性心力衰竭、腦出血、多發性硬化症、中性粒細胞減少症、血小板減少症、貧血症、肝炎、類風濕性關節炎、哮喘、克羅恩病等。使用重組 DNA 技術製造的疫苗基於編碼來自特定病毒病原體的蛋白質的生物構建體的表達。這些疫苗由實驗室合成的蛋白質或糖蛋白亞基製成。

預計表達系統部分將在預測期內表現出最快的增長率

按成分，市場分為表達系統和克隆載體。表達系統對於所選宿主細胞中的蛋白質表達至關重要。開發高效的蛋白質表達系統已成為全球範圍內的大規模活動。該市場主要由幾種表達系統的可用性主導，例如細菌表達系統、酵母表達系統、桿狀病毒表達系統和哺乳動物表達系統。表達系統的選擇取決於許多因素，包括目標蛋白特性、預期用途、蛋白產量和成本。酵母表達系統是一種新的外源蛋白表達系統，它結合了原核和真核表達系統的特點。酵母表達系統廣泛用於基因工程領域。在哺乳動物細胞表達系統中表達的重組蛋白通過質粒轉染或病毒載體感染來表達。越來越多的研究評估植物作為生產轉基因產品的表達系統的潛力。

區域分析

北美在重組 DNA 技術的全球市場中佔有最大份額。

北美地區在 2019 年佔據全球重組 DNA 技術市場的最大市場份額，因為該地區在製藥、農業、工業和研究領域廣泛採用重組 DNA 技術。隨著慢性病的興起，重組DNA技術在疾病預防、治療和管理方面的應用正在興起。由於存在許多生物製藥製造商，美國的市場份額最高。先進的重組 DNA 技術在獸藥、轉基因作物和生物農藥的開發中的使用越來越多。研究人員還使用重組 DNA 技術來改進用於生物燃料生產的生物質。

生物製藥的研發活動也很活躍。多家公司已與研究機構、組織和團體合作開發生物製藥。例如，2020 年 2 月，賽諾菲與美國衛生與公眾服務部防備和應對助理部長辦公室下屬的生物醫學高級研究與發展局 (BARDA) 合作開發重組疫苗新型冠狀病毒。簽署。根據協議，賽諾菲將使用無卵重組 DNA 平台生產其 COVID-19疫苗。 BARDA 將提供專業知識和重新分配的資金來支持疫苗開發。 2019 年 12 月，賽諾菲與生物醫學高級研究與發展局 (BARDA) 建立合作夥伴關係，在美國建立最先進的設施，用於生產佐劑重組大流行性流感疫苗。

預計亞太地區將在預測期內以最快的複合年增長率增長

由於開發重組 DNA 技術產品的市場參與者越來越多，亞太地區是全球重組 DNA 技術市場中增長最快的地區。由於擁有熟練且廉價的勞動力，一些公司正在將其製造基地轉移到亞太地區。人類健康、食品和農業對重組和轉基因產品的需求不斷增加。

公司正在使用轉基因作物來提高作物產量、降低食品和藥品生產成本、減少對農藥的使用需求、提高營養成分和食品質量以及增強對病蟲害的抵抗力。我們專注於改進重組 DNA 技術用於作物生產。重組 DNA 技術在藥學、基因治療、疫苗設計和生物修復方面的選擇性改進正在取得進展。一些組織、協會和研究機構正在資助和投資重組 DNA 技術在醫療保健、食品和農業中的使用。

競爭格局。

重組 DNA 技術市場是一個分散的市場，市場參與者眾多。 F. Hoffmann-La Roche Ltd, Biogen, Amgen Inc, Novartis AG, Eli Lilly and Company, Pfizer Inc, Novo Nordisk A/S, Sanofi, Merck KGaA, GlaxoSmithKline plc, Thermo Fisher Scientific, Inc 擁有很大的市場份額 成為播放器。領先的公司採用了多種增長戰略，例如產品發布、產品批准、合併、許可、收購和合作夥伴關係，為重組 DNA 技術市場的全球增長做出了貢獻。例如：

合併和合作。

2021 年 5 月 21 日，Biogen 宣布已與 Ginkgo Bioworks 就開發新型基因療法製造平台的許可協議進行合作。

2020 年 1 月 2 日，安進宣布與百濟神州結成戰略聯盟，以擴大其在中國的腫瘤業務。

產品發布和批准

2021 年 8 月 3 日，Ameghan 宣佈在 Holly Springs 建設一個價值 5.5 億美元的生物製劑製造工廠。

2019 年 4 月 1 日，金斯瑞推出了基於 CRISPR 的基因編輯的單鏈 DNA 服務。這項新服務將為研究人員提供用於基於 CRISPR 的基因插入以及最終用於癌症研究和治療的基因治療、細胞治療、轉基因治療的高質量、純 ssDNA，這將有助於加速遺傳動物模型的開發。

收購

2020 年 10 月，Proteintech 收購了 Cameroid、單域抗體或納米抗體製造商 ChromoTek。 ChromoTek 是用於突破性研究發現的納米抗體高性能重組試劑的市場領導者。

合作夥伴關係

2020 年 8 月，Novavax 與武田製藥有限公司建立合作夥伴關係，在日本開發、製造和商業化用於 COVID-19 的 NVX-CoV2373。 NVX-CoV2373 是一種穩定的預融合蛋白，採用 Novavax 的重組蛋白納米顆粒技術開發，包括 Novavax 的專有 Matrix-M 佐劑。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按產品類型劃分的市場細分
  • 按組件劃分的市場細分
  • 按應用劃分的市場細分
  • 最終用戶的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 技術進步
      • 生物製藥的興起
    • 限制因素
      • 監管、科學和道德問題
      • 與使用重組 DNA 技術相關的風險
    • 商機
    • 影響分析

第5章行業分析

  • 波特五力分析
  • 流行病學
  • 管道分析
  • 供應鏈分析
  • 定價分析
  • 法律法規分析
  • 保險報銷分析
  • 未滿足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按產品類型

    • 醫療
      • 治療藥
      • 人體蛋白質
      • 疫苗
    • 非醫療
      • 生物作物
      • 特種化學品
      • 其他

第 8 章按組件

    • 表達系統
      • 哺乳動物
      • 細菌
      • 酵母
      • 桿狀病毒/昆蟲
      • 其他
    • 克隆載體

第 9 章。按應用程序

  • 食品和農業
  • 健康與疾病
  • 環境
  • 其他

第 10 章，最終用戶

  • 生物技術公司、製藥公司
  • 學術和政府研究機構
  • 其他

第 11 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 12 章競爭格局

  • 競爭場景
  • 市場情況/份額分析
  • 併購分析

第 13 章公司簡介

  • 孟山都公司
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • F. Hoffmann-La Roche Ltd
  • Biogen
  • Amgen Inc
  • Novartis AG
  • Eli Lilly and Company
  • GenScript
  • Pfizer Inc.
  • Novo Nordisk A/S
  • Sanofi
  • Merck KGaA
  • Profacgen
  • Biocon
  • GlaxoSmithKline plc.
  • Cibus
  • Horizon Discovery Group plc
  • New England Biolabs
  • Thermo Fisher Scientific, Inc.（LIST NOT EXHAUSTIVE）

第14章 DataM

簡介目錄
Product Code: DMPH2798

Market Overview

Recombinant DNA Technology Market was valued at USD 156.75 billion in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 4.80% during the forecast period (2022-2029).

Recombinant DNA technology includes the insertion of the DNA into the genome with the gene of interest. It produces new genetic combinations by joining the DNA molecules from two different species and inserted into the host organism. The new genetic combination includes the genetic material from multiple sources not found in the genome. It results in the production of genetically modified organisms and products. Genetically modified organisms such as microorganisms, animals, and plants have shown enhanced product yield and increased adaptability for better survival.

Several companies are using recombinant DNA technology for producing insulin, Follistim, human growth hormones, monoclonal antibodies, human albumin, vaccines, gene therapy and other therapeutics. It is also used for producing genetically modified crops, cloned animals, biopesticides, biofuel, and other products.

Market Dynamics

Technology Advancement of Recombinant DNA Technology is Driving the Growth of the Market

The market is witnessing technological advancement for developing efficient diagnostic tools and therapeutics. The introduction of the Bac-to-Bac baculovirus expression systems provided an efficient method to produce recombinant baculovirus with desired genes in insect cells. Bac-to-Bac baculovirus expression systems have accelerated the cloning reaction compared to the restriction enzyme cloning which consumes a lot of time. CRISPR technology can alter DNA sequences and modify gene function. It is used in various applications such as correcting genetic defects, treating and preventing the spread of diseases and improving crops. There is increasing adoption of germline gene therapy to transfer the DNA into the cells that produce reproductive cells, eggs or sperm, in the body. This therapy is beneficial for correcting disease-causing gene variants that can be passed from generation to generation. Somatic gene therapy is used for transferring the DNA into the body tissues. It targets the body cells that are not passed from generation to generation.

Increasing Funding & Investment for Development of Recombinant Products is Expected to Fuel the Market Growth over the Forecast Period

Several organizations, associations, and institutes are raising the funding & investment for developing recombinant products. For instance, in March 2020, the Coalition for Epidemic Preparedness Innovations (CEPI), had invested USD 4.4 million in collaboration agreements with Novavax, Inc. and The University of Oxford to rapidly develop recombinant vaccine products against COVID-19. Under the terms of the agreement, CEPI would provide initial funding to Novavax to enable preparations for phase I trials. The University of Oxford would support the manufacture of vaccine materials required for preclinical and phase I testing. In July 2020, the United States Departments of Health and Human Services (HHS) and Defense (DoD) awarded the funding of USD 2.1 billion to Sanofi and GlaxoSmithKline for the development and manufacturing of the recombinant protein-based COVID-19 vaccine. Health and Human Services (HHS) and Defense (DoD) would provide the funding for Operation Warp Speed.

Ethical Issues Regarding the Use of Recombinant Products is Hampering the Market Growth

There are several ethical issues are associated with the use of recombinant products. There are several concerns including whether the recombinant products are biologically equivalent to the natural product, and recombinant proteins can result in immunogenic reactions that could limit their use. The use of the recombinant product is tampering with the genome. Differences in immunological sensitivities in animal and human systems have demonstrated disastrous effects. TeGenero trial conducted for testing an antibody TGN1412 among the patients with rheumatoid arthritis and B-cell chronic lymphocyte leukaemia has shown the harmful effects. Germ-cell gene therapy would ultimately diminish the human gene pool by removing genes considered to be bad. Only rich people would be benefited due to the high cost of gene therapy. The widespread use of gene therapy can make society to least accept the people who are different. There are also ethical concerns regarding gene therapy for enhancing basic human traits such as height, intelligence, or athletic ability.

COVID-19 Impact Analysis

The global recombinant DNA technology market has witnessed drastic growth due to the COVID-19 pandemic as several biopharmaceutical companies are focusing on developing the vaccine by using recombinant DNA technology for the prevention of COVID-19. There is increasing research and development activities for developing the recombinant vaccine for COVID-19 with the rising number of people being affected by the COVID-19 infection. The pipeline comprised of several viral vectors, nucleic acid-based vaccines and antigen-presenting cells being developed for COVID-19. Viral vector vaccines are comprised of the recombinant virus that is attenuated to reduce its pathogenicity, and genes encoded with viral antigens are cloned using recombinant DNA techniques. Protein-based vaccines comprised of the protein purified from the virus or virus-infected cells, recombinant protein or virus-like particles

Several organizations, associations, institutes, and companies are entering into the collaboration for the development of a recombinant vaccine for COVID-19 infection. For instance, in April 2020, Sanofi had entered into the collaboration with GlaxoSmithKline plc to develop an adjuvanted vaccine for COVID-19. Under the terms of the agreement, Sanofi would contribute its S-protein COVID-19 antigen based on recombinant DNA technology. GlaxoSmithKline plc would contribute its proven pandemic adjuvant technology. This may be useful to produce more vaccine doses with the reduced amount of vaccine protein required per dose and thus protect more people.

Epidemiology

Chronic diseases are the leading cause of mortality and morbidity worldwide. According to the Centers for Disease Control and Prevention (CDC), around, 6 out of 10 adults are suffering from chronic diseases. Approximately, 4 out of 10 people develop two or more chronic diseases. Heart disease, cancer, chronic lung disease, stroke, Alzheimer's disease, diabetes, and chronic kidney disease are the most common chronic diseases. Tobacco consumption, poor nutrition, lack of physical activity, excessive alcohol use, and other disorders increase the risk of developing chronic diseases. According to the American Diabetes Association, approximately 34.2 million are suffering from diabetes in the United States. Out of these people, around 1.6 million are affected by type 1 diabetes.

Market Segment Analysis

The medical segment is expected to hold the largest share in the Recombinant DNA Technology market

By Product Type, the medical segment is anticipated to hold the largest share in the recombinant DNA technology treatment market owing to the higher adoption of recombinant DNA technology for producing pharmaceutical products. Recombinant DNA technology produces novel pharmaceutical products, safer or more effective versions of conventionally produced pharmaceuticals, and substances identical to conventionally made pharmaceuticals. The medical segment is classified as the therapeutic agent, human protein, and vaccine. Recombinant DNA technology is used to produce human proteins that can be used as diagnostic tools and therapeutics to treat various genetically linked diseases. Various recombinant proteins such as recombinant hormones, interferons, interleukins, growth factors, tumour necrosis factors, blood clotting factors, thrombolytic drugs, and enzymes are useful for the treatment of the diseases such as diabetes, dwarfism, myocardial infarction, congestive heart failure, cerebral apoplexy, multiple sclerosis, neutropenia, thrombocytopenia, anaemia, hepatitis, rheumatoid arthritis, asthma, Crohn's disease, and others. Vaccines produced by using recombinant DNA technology are based on the expression of biological constructs encoding proteins from specific viral pathogens. These vaccines are made of protein or glycoprotein subunits synthesized in the laboratory.

Expression System Segment is Anticipated to Grow at the Fastest Growth Rate over the Forecast Period

By component, the market is segmented into an expression system and cloning vector. Expression systems are essential for expressing the proteins within the chosen host cell. There is increasing development of efficient protein expression systems at a large scale across the globe. The market is dominated by the availability of several expression systems such as bacteria expression system, yeast expression system, baculovirus expression system and mammalian expression system. The choice of the expression systems depends on various factors such as target protein property, intended application, protein yield and cost. The yeast expression system is the new exogenous protein expression system that contains the characteristics of both prokaryotic and eukaryotic expression systems. There is high usage of the yeast expression system in genetic engineering. The recombinant proteins expressed in the mammalian cell expression system includes the use of plasmid transfection and viral vector infection. There is increasing research for evaluating the potential of plants as the expression system for the production of genetically modified products.

Geographical Analysis

North America region holds the largest market share global Recombinant DNA Technology market

North America region is dominating the global recombinant DNA technology market accounted for the largest market share in 2019 due to higher adoption of the recombinant DNA technology in medicines, agriculture, industries, and research. There is increasing recombinant DNA technology for the prevention, treatment, and management of diseases with the increasing prevalence of chronic diseases. The United States accounts for the highest market share due to the presence of a large number of biopharmaceutical manufacturing companies. There is rising usage of advanced recombinant DNA technologies for developing veterinary products, genetically modified crops, and biopesticides. Researchers are also using recombinant DNA technology to alter the biomass for improving its use for biofuel production.

There is increasing research and development activities for biopharmaceuticals. Several companies are entering into collaboration with institutes, organizations, and associations for developing biopharmaceuticals. For instance, in February 2020, Sanofi had entered into collaboration with the Biomedical Advanced Research and Development Authority (BARDA), a component of the United States Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response for the development of the recombinant vaccine for novel coronavirus. Under the terms of the agreement, Sanofi would use its egg-free, recombinant DNA platform to produce a vaccine for novel coronavirus. BARDA would provide the expertise and reallocated funds to support the vaccine's development. In December 2019, Sanofi had entered into the collaboration with the Biomedical Advanced Research and Development Authority (BARDA) to establish the state-of-the-art facilities in the United States for the production of an adjuvanted recombinant vaccine for the influenza pandemic.

Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period

Asia-Pacific region is the fastest-growing region in the global recombinant DNA technology market as there is an increase in market players developing recombinant DNA technology products. Several companies are shifting their manufacturing base to the Asia-Pacific region due to the availability of skilled and cheap labourers. There is rising demand for recombinant and genetically modified products for human health, food and agriculture.

Companies are focusing on improving the recombinant DNA technology for the production of genetically modified crops to increase crop yields, reduce costs for food or drug production, reduce the need for use of pesticides, enhance the nutrient composition and food quality, resistance to pests and disease. There is growing penetration of recombinant DNA technology for providing selective improvements in pharmaceutics, gene therapy, vaccine design and bioremediation. Several organizations, associations, and institutes are raising the funding & investment for the use of recombinant DNA technology for healthcare, food and agriculture.

Competitive Landscape:

The recombinant DNA technology market studied is a fragmented market with a large number of market players. F. Hoffmann-La Roche Ltd, Biogen, Amgen Inc, Novartis AG, Eli Lilly and Company, Pfizer Inc., Novo Nordisk A/S, Sanofi, Merck KGaA, GlaxoSmithKline plc., and Thermo Fisher Scientific, Inc are the market players with the significant market share. The major players are adopting several growth strategies such as product launches, product approvals, mergers, licensing, acquisitions, and collaborations, contributing to the growth of the recombinant DNA technology market globally. For instance,

Mergers & Collaborations:

On 21st May 2021, Biogen announced it collaborated with Ginkgo Bioworks on a license agreement to develop a Novel Gene Therapy Manufacturing platform.

On 2nd January 2020, Amgen announced it has a strategic collaboration with BeiGene to expand its oncology presence in China.

Product Launch & Approvals:

On 3rd August 2021, Amegan Inc announced that it will build its Biologics Manufacturing Facility with 550 million USD in Holly Springs.

On 1st April 2019, GenScript launched a Single-stranded DNA Service for CRISPR-based Gene Editing. The new service offers researchers access to high-quality, pure ssDNA for CRISPR-based gene insertion, ultimately helping to accelerate the development of gene therapy, cell therapy, and transgenic animal models for cancer research and treatment.

Acquisition:

In October 2020, Proteintech acquired ChromoTek, a manufacturer of Camelid, single-domain antibodies i.e., nanobodies. ChromoTek is the market leader in nanobodies high-performance recombinant reagents for breakthrough research discoveries.

Partnership:

In August 2020, Novavax, Inc had entered into a partnership with Takeda Pharmaceutical Company Limited for the development, manufacturing and commercialization of NVX-CoV2373 for COVID-19 in Japan. NVX-CoV2373 is a stable, prefusion protein developed using the Novavax' recombinant protein nanoparticle technology and includes Novavax' proprietary Matrix-M adjuvant.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Product Type
  • 3.2. Market Snippet by Component
  • 3.3. Market Snippet by Application
  • 3.4. Market Snippet by End-User
  • 3.5. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Technological Advancements
      • 4.1.1.2. Rising of Biopharmaceutical Industry
      • 4.1.1.3. XX
    • 4.1.2. Restraints:
      • 4.1.2.1. Regulatory, scientific, and ethical challenges
      • 4.1.2.2. Risk associated with use of Recombinant DNA Technology
      • 4.1.2.3. XX
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology
  • 5.3. Pipeline Analysis
  • 5.4. Supply Chain Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
  • 7.3. Market Attractiveness Index, By Product Type Segment
    • 7.3.1. Medical*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
      • 7.3.1.3. Therapeutic Agent
      • 7.3.1.4. Human Protein
      • 7.3.1.5. Vaccine
    • 7.3.2. Non-medical
      • 7.3.2.1. Biotech Crops
      • 7.3.2.2. Specialty Chemicals
      • 7.3.2.3. Other

8. By Component

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Component
  • 8.3. Market Attractiveness Index, By Component Segment
    • 8.3.1. Expression System*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
      • 8.3.1.3. Mammalian
      • 8.3.1.4. Bacteria
      • 8.3.1.5. Yeast
      • 8.3.1.6. Baculovirus / Insect
      • 8.3.1.7. Others
    • 8.3.2. Cloning Vector

9. By Application

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 9.3. Market Attractiveness Index, By Application Segment
    • 9.3.1. Food and Agriculture*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Health and Disease
    • 9.3.3. Environment
    • 9.3.4. Others

10. By End-User

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 10.3. Market Attractiveness Index, By End-User Segment
    • 10.3.1. Biotechnology and Pharmaceutical Companies*
      • 10.3.1.1. Introduction
      • 10.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 10.3.2. Academic and Government Research Institutes
    • 10.3.3. Others

11. By Region

  • 11.1. Introduction
  • 11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 11.3. Market Attractiveness Index, By Region
  • 11.4. North America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Component
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. U.S.
      • 11.4.7.2. Canada
      • 11.4.7.3. Mexico
  • 11.5. Europe
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Component
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. Germany
      • 11.5.7.2. U.K.
      • 11.5.7.3. France
      • 11.5.7.4. Italy
      • 11.5.7.5. Spain
      • 11.5.7.6. Rest of Europe
  • 11.6. South America
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Component
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.6.7.1. Brazil
      • 11.6.7.2. Argentina
      • 11.6.7.3. Rest of South America
  • 11.7. Asia Pacific
    • 11.7.1. Introduction
    • 11.7.2. Key Region-Specific Dynamics
    • 11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Component
    • 11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.7.7.1. China
      • 11.7.7.2. India
      • 11.7.7.3. Japan
      • 11.7.7.4. Australia
      • 11.7.7.5. Rest of Asia Pacific
  • 11.8. Middle East and Africa
    • 11.8.1. Introduction
    • 11.8.2. Key Region-Specific Dynamics
    • 11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Component
    • 11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Monsanto Company*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. F. Hoffmann-La Roche Ltd
  • 13.3. Biogen
  • 13.4. Amgen Inc
  • 13.5. Novartis AG
  • 13.6. Eli Lilly and Company
  • 13.7. GenScript
  • 13.8. Pfizer Inc.
  • 13.9. Novo Nordisk A/S
  • 13.10. Sanofi
  • 13.11. Merck KGaA
  • 13.12. Profacgen
  • 13.13. Biocon
  • 13.14. GlaxoSmithKline plc.
  • 13.15. Cibus
  • 13.16. Horizon Discovery Group plc
  • 13.17. New England Biolabs
  • 13.18. Thermo Fisher Scientific, Inc. (LIST NOT EXHAUSTIVE)

14. DataM Intelligence

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us